---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-004663"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2023-04-13T23:59:59+00:00"
generated_at: "2026-06-17T02:49:37.352915+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tenax prioritizes oral levosimendan Phase 3 for PH-HFpEF in 2023

## Summary
- Company to initiate Phase 3 trial of TNX-103 (oral levosimendan) for PH-HFpEF in 2023.
- PH-HFpEF affects >1.6M North Americans; no FDA-approved therapy exists.
- Patent estate expanded; protection through at least 2040 with additional IP expected in 2023.
- FDA agreed Phase 3 endpoints: 6-minute walk distance at 12 weeks or clinical worsening at 24 weeks.
- Imatinib Phase 3 deferred beyond 2023 pending fundraising and strategic review.

## SEC filing metadata
- accession: 0001654954-23-004663
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2023-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495423004663/0001654954-23-004663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495423004663/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-004663
- JSON: https://secwatch.observer/filing/0001654954-23-004663.json
- Plain text: https://secwatch.observer/filing/0001654954-23-004663.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.